杨凡-T细胞及NK细胞肿瘤流式细胞分析
In recent decades, adoptive cell therapies have emerged as promising approaches for harnessing the endogenous cytotoxicity of immune cells and destroying malignant cells. Among immune cell candidates, natural killer (NK) cells have drawn significant attention due to their unique ability to recognize and ...
27. 216 Dual targeting of CAR-NK cells to PD-L1 and ErbB2 facilitates specific elimination of cancer cells of solid tumor origin and overcomes immune escape by antigen loss. Jiri Eitler et al.28. NK Cell Metabolism and TGFβ - Implications for Immunotherapy. [PMID: 31921174]29. Cordycep...
5. Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. [PMID: 28572802] 6. Influence of Galectin-9 Treatment on the Phenotype and Function of NK-92MI Cells in the Presence...
2. Unique advantages of CAR-engineered NK cells 3. Generation of CAR-NK cells 4. Clinical applications of CAR-NK cells 5. CAR-NK cell therapy in the near future 6. Conclusion 7. Outstanding questions Search strategy and selection criteria Originality of figures Author contributions Declaration of...
were exhibited in all the patients . Cytopenia were seen in 18 cases. Morphologically, atypical large granular lymphocytes and hemophagocytosis were common in bone marrow smears . Loss of CD5 or CD7 expression were frequently observed in T/NK lymphocytes by flow cytometry of bone marrow cells. ...
4.2 Hobit Hobit(homolog of Blimp1 in T cells)在小鼠LrNK细 胞中的表达水平显著高于cNK细胞, Hobit基因缺陷导 致NK细胞缺失, 但肝脏和脾脏cNK细胞数量不受影 响, 说明Hobit特异性调控LrNK细胞[60]. 不仅如此, Ho- bit还能调控其他类型的驻留淋巴细胞, 如组织驻留记 忆T细胞,NKT细胞, 但在这些细胞中, ...
NK/T-cell lymphoma (NKTCL) is an EBV-related malignant tumor, most of which originates from natural killer (NK) cells, and only a few originate from T cells [55]. It can be divided into nasal, non-nasal and diffuse. In patients with NKTCL, the rate of EB virus positivity is more ...
As recently shown, in tumor patients, NK cells may also express inhibitory checkpoints, primarily PD-1. Accordingly, the therapeutic use of checkpoint inhibitors may unleash NK cells against PD-L1+ tumors. This effect may be predominant and crucial in tumors that have lost HLA cl-I expression...
NK cells by graft ECs. We find that graft ECs are unable to deliver inhibitory signals to recipient NK cells because of different (mismatched) HLA class I molecules (HLA I). This mimics the “missing self” for NK cells, and we show that this is sufficient to provoke EC damage in ...